Combining HAIC, Lenvatinib, and PD-1 Inhibitors for Unresectable HCC
Author Information
Author(s): Wei Min, Zhang Pengwei, Yang Chaofeng, Li Yang
Primary Institution: Sichuan Key Laboratory of Medical Imaging, Department of Radiology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Hypothesis
Does combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and PD-1 inhibitors improve treatment outcomes for advanced, unresectable hepatocellular carcinoma (HCC)?
Conclusion
The combination of HAIC with lenvatinib and PD-1 inhibitors significantly enhances treatment effectiveness for unresectable HCC.
Supporting Evidence
- The combination treatment significantly improved overall survival (OS) and progression-free survival (PFS).
- Trial sequential analysis confirmed that the data were sufficient to draw reliable conclusions about the objective response rate (ORR) and disease control rate (DCR).
- Patients with high tumor burden or those refractory to transarterial chemoembolization (TACE) benefited particularly from this treatment approach.
Takeaway
This study shows that using three treatments together can help people with a serious liver cancer live longer and feel better.
Methodology
A meta-analysis of 8 cohort studies was conducted, analyzing data from clinical trials that evaluated the combination of HAIC, lenvatinib, and PD-1 inhibitors.
Potential Biases
Potential biases in data selection and analysis due to the retrospective nature of the studies.
Limitations
All included studies were retrospective, which may introduce biases and affect the reliability of the results.
Participant Demographics
The majority of participants were male, aged between 50 and 65 years, with a high tumor burden.
Statistical Information
P-Value
p<0.00001
Confidence Interval
[95% CI 0.45, 0.63]
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website